NATHAN KING: Open Payments
NPI 1548934128 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,175 in 73 payments from 14 companies in 2025. Trend: 2023 $266 · 2024 $1,421 · 2025 $1,175
Food & beverage: $1,175
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $505 |
| Alkermes, Inc. | 7 | $159 |
| Lundbeck LLC | 7 | $120 |
| Neurocrine BioSciences, Inc. | 3 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 1 | $36 |
| Janssen Pharmaceuticals, Inc | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
Products named: VRAYLAR, REXULTI, LYBALVI, ARISTADA, INGREZZA, CAPLYTA, Jornay PM, Qelbree.
Industry payments across PA — which companies pay providers there.
